Ovid Therapeutics Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.3 | $0.6 | $0.4 | $1.5 | $208.4 |
| Operating income | -$42.4 | -$61.9 | -$59.3 | -$55.5 | $124.2 |
| Net income | -$17.4 | -$26.4 | -$52.3 | -$54.2 | $122.8 |
| Cash Flow Statement | |||||
| Free cash flow | -$38.3 | -$56.0 | -$45.8 | -$56.5 | $118.4 |
Shares outstanding 186.6M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of July 14, 2026.